Market Trends of Global Chemiluminescence Immunoassay (CLIA) Industry
This section covers the major market trends shaping the Chemiluminescence Immunoassay (CLIA) Market according to our research experts:
Oncology Segment is Expected to Hold the Largest Market Share
The increasing number of cancer cases globally has led to the development of several research and developments for the detection, diagnosis, and treatment of the disease. As cancer is one of the most diagnosed rare diseases, the development of treatment and diagnosis methods for the disease remains a priority for researchers and scientists. Several research has found that the use of novel and verified biomarkers can lead to the early diagnosis of various cancers, the demand for the chemiluminescence immunoassay (CLIA) for oncology studies increased, and the demand is expected to grow over the forecast period. This is expected to fuel the segment growth.
There is an increase in cancer cases globally. According to Global Cancer Observatory data updated in 2021, the new cancer cases that were diagnosed in the previous year accounted for 19.3 million globally. Additionally, World Health Organization (WHO) data updated in February 2022 stated that nearly 400,000 children develop cancer, and the most common cancers vary between countries. While breast, lung, colon and rectum, and prostate cancers are the most common cancers globally. In addition, several research has proven the efficiency of sensitive chemiluminescence (CL) imaging immunoassay methods for the detection of multiple tumor markers with high throughput and easy operation. Thus, this burden of cancer globally is anticipated to create demand for the CLIA methods, driving the segment growth.
Furthermore, the research article 'A novel automated immunoassay for serum NY-ESO-1 and XAGE1 antibodies in the combinatory prediction of response to anti-programmed cell death-1 therapy in non-small-cell lung cancer' published in August 2021 stated that when the researchers conducted the research with the aim to develop a fully automated immunoassay system measuring NY-ESO-1/XAGE1 antibodies (Abs), they automated the procedures using high sensitivity chemiluminescent enzyme immunoassay (HISCL) and the results were positive and the immunoassay method using HISCL found to be useful to predict clinical benefits with non-small-cell lung cancer (NSCLC) immune-checkpoint therapy. Thus, such research is increasing in the oncology segment and showing the benefits of the CLIA methods, driving the segment growth.
Thus, owing to advanced research and development the segment is expected to witness growth over the forecast period.
North America is Expected to Dominate the Market Over the Forecast Period
North America is expected to dominate the overall chemiluminescence immunoassay (CLIA) market, throughout the forecast period. This is owing to factors such as the rising incidence of chronic diseases such as cardiovascular diseases and cancer and the revolution in test offerings is among the major factors driving the market over the forecast period.
The United States holds the largest market share owing to factors such as the increasing number of populations suffering from cardiovascular diseases and other chronic diseases. As per the CDC (Centers for Disease Control and Prevention) data updated in February 2022, coronary artery disease, ischemic heart disease, or history of myocardial infarction accounted for 7.2% of emergency room visits currently, and the data updated in January 2022 by CDC shows that number of visits to emergency departments with stroke as the primary diagnosis was 432,000 in the previous year.
In addition, according to the American Academy of Dermatology Association, more than 1 million Americans are living with melanoma. In the United States, 197,700 new cases of melanoma will be diagnosed in 2022, with 97,920 non-invasive (in situ) and 99,780 invasive cases. Melanoma claims the lives of over 20 Americans every day. Melanoma is anticipated to kill 7,650 people in 2022, with 5,080 males and 2,570 women dying. Thus, the increasing prevalence and burden of chronic diseases in the country demand for effective diagnosis and treatment methods, thereby resulting in increased use of CLIA methods. This is expected to contribute to the growth of the studied market.
Therefore, owing to the factors mentioned above, the market studied is expected to grow in the region over the forecast period.
